Enspryng Market Report 2026

Enspryng Market Overview

• The Enspryng market growth in the historic period has been driven by limited treatment options for nmosd, increased awareness of autoimmune neurology disorders • Market expansion is supported by expansion of biologics in neurology, increasing diagnosis of rare demyelinating diseases • Growth Driver: Rising Prevalence Of Multiple Sclerosis Driving Growth In The Enspryng Market • Market Trend: Regulatory Approvals And Market Expansion Of Enspryng (Ofatumumab) For New Indications • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Enspryng Market?

Enspryng (satralizumab) is a monoclonal antibody used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults with aquaporin-4 antibodies by inhibiting the interleukin-6 receptor to reduce inflammation. Administered subcutaneously every four weeks following a loading phase, its common side effects include headache and increased infection risk. The main types of indications in enspryng are Neuromyelitis Optica Spectrum Disorder (NMOSD) and Generalized Myasthenia Gravis (gMG). Neuromyelitis optica spectrum disorder (NMOSD) refers to a rare autoimmune disease that primarily affects the central nervous system, particularly the optic nerves and spinal cord. This drug can be used for various age demographics, including age groups and seropositivity, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Enspryng Market Growth Forecast?

The growth in the forecast period can be attributed to expansion of biologics in neurology, increasing diagnosis of rare demyelinating diseases, demand for long term relapse prevention, favorable biologic reimbursement trends, ongoing neuroimmunology research. Major trends in the forecast period include interleukin-6 targeted neurology therapies, growth of rare neuroimmunology treatments, shift toward long acting injectable biologics, expansion of personalized autoimmune care, increased focus on relapse prevention.

Global Enspryng Market Segmentation

1) By Indication: Neuromyelitis Optica Spectrum Disorder (NMOSD), Generalized Myasthenia Gravis (gMG) 2) By Patient Demographics: Age Groups, Seropositivity 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

What Are The Drivers Of The Enspryng Market?

The rising prevalence of multiple sclerosis is expected to propel the growth of the enspryng market going forward. Multiple Sclerosis (MS) is a chronic disease of the central nervous system (CNS) that affects the brain and spinal cord. The rising prevalence of multiple sclerosis is largely attributed to improved diagnosis through advanced imaging techniques and better reporting, which has led to earlier and more accurate detection of the disease. Enspryng (satralizumab) is used to treat relapsing forms of multiple sclerosis by blocking the interleukin-6 receptor to reduce inflammation and prevent nerve damage, administered via monthly subcutaneous injections. For instance, in May 2024, according to the Multiple Sclerosis Society, a UK-based charity for people affected by multiple sclerosis, each year, over 7,100 people are diagnosed with MS, with 71% of them being women, making women 2.5 times more likely than men to develop the condition. Therefore, the rising prevalence of multiple sclerosis is driving the growth of the enspryng industry. Increasing investment for healthcare is expected to propel the growth of the enspryng market going forward. Investment for healthcare refers to the allocation of financial resources, including capital and operational funds, into healthcare-related initiatives, technologies, and services. The rapid adoption of telemedicine and AI-driven diagnostics is driving significant investment in healthcare, as these technologies promise improved patient outcomes and operational efficiencies. Investment in healthcare has supported the development, regulatory approval, manufacturing, and global distribution of enspryng, ensuring its accessibility for patients with neuromyelitis optica spectrum disorder. For instance, in November 2024, according to the Health Foundation, a UK-based independent charity, the planned healthcare spending will rise from approximately $221.1bn (£177.9bn) in cash terms to $237.4bn (£190.1bn) in 2024/25 and $250.1bn (£200.5bn) in 2025/26. After accounting for changes in pensions policy, this represents an average annual real-term growth of 3.3% since 2023/24. Therefore, increasing investment for healthcare is driving the growth of the enspryng industry.

Key Players In The Global Enspryng Market

Major companies operating in the enspryng market are F. Hoffmann-La Roche AG

Global Enspryng Market Trends and Insights

A key trend in the enspryng (Ofatumumab) market is obtaining regulatory product approvals to expand its clinical indications. Regulatory product approvals refer to the formal process through which a government or regulatory body evaluates and authorizes a product for sale and use in a specific market. For instance, in June 2021, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical company, received approval from the European Commission for Enspryng (satralizumab), as the first and only at-home subcutaneous treatment for neuromyelitis optica spectrum disorder (NMOSD), specifically targeting patients with anti-aquaporin-4 (AQP4-IgG) antibodies. This innovative therapy can be self-administered every four weeks after proper training, enhancing convenience for patients compared to traditional intravenous treatments. Clinical trials demonstrated significant efficacy, with a 74% reduction in relapse risk and a favorable safety profile.

Regional Insights

North America was the largest region in the enspryng market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Enspryng Market?

The enspryng market consists of sales of products including satralizumab and prefilled syringes and monotherapy products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Enspryng Market Report 2026?

The enspryng market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the enspryng industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.